Evidence map›Paper›PMID 36037065›Full record

ArticleCellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology2022

Acid Sphingomyelinase-Ceramide Induced Vascular Injury Determines Colorectal Cancer Stem Cell Fate.

Christy Li, Stefan Klingler, Sahra Bodo, Jin Cheng, Yan Pan, Mohammed Adileh, Maria Laura Martin, John Fuller, Regina Feldman, Adam Michel and 3 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Christy LiLaboratory of Signal Transduction Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Stefan KlinglerLaboratory of Signal Transduction Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Sahra BodoLaboratory of Signal Transduction Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Jin ChengLaboratory of Signal Transduction Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Yan PanLaboratory of Signal Transduction Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Mohammed AdilehLaboratory of Signal Transduction Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Maria Laura MartinLaboratory of Signal Transduction Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
John FullerLaboratory of Signal Transduction Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Regina FeldmanLaboratory of Signal Transduction Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Adam MichelLaboratory of Comparative Pathology, Rockefeller University, Weill Cornell Medicine and Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Zhigang ZhangDepartment of Epidemiology and Biostatistics Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Zvi FuksDepartment of Radiation Oncology Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Richard KolesnickLaboratory of Signal Transduction Memorial Sloan-Kettering Cancer Center, New York, NY, USA, r-kolesnick@ski.mskcc.org.
Memorial Sloan Kettering Cancer Center · USCornell University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Re-setting the Endothelial Ceramide RheostatR01CA158367 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KOLESNICK, RICHARD N · 2012 to 2016
$1.9M
Larry and Stephanie Flinn FoundationMr. William H. Goodwin and Mrs. Alice Goodwin and the Commonwealth Foundation for Cancer ResearchNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA158367The Center Experimental Therapeutics at Memorial Sloan Kettering CancerVirginia and D.K. Ludwig Fund for Cancer Research
6 · The paper itself

Abstract

BACKGROUND/

aimsIt is unknown whether cancer stem cells respond differentially to treatment compared with progeny, potentially providing therapeutic vulnerabilities. Our program pioneered use of ultra-high single dose radiotherapy, which cures diverse metastatic diseases at a higher rate (90-95%) than conventional fractionation (~65%). Single dose radiotherapy engages a distinct biology involving microvascular acid sphingomyelinase/ceramide signaling, which, via NADPH oxidase-2-dependent perfusion defects, initiates an adaptive tumor SUMO Stress Response that globally-inactivates homologous recombination repair of double stand breaks, conferring cure. Accumulating data show diverse stem cells display heightened-dependence on homologous recombination repair to repair resolve double stand breaks.

methodsHere we use colorectal cancer patient-derived xenografts containing logarithmically-increased Lgr5+ stem cells to explore whether optimizing engagement of this acid sphingomyelinase dependent biology enhances stem cell dependent tumor cure.

resultsWe show radioresistant colorectal cancer patient-derived xenograft CLR27-2 contains radioresistant microvasculature and stem cells, whereas radiosensitive colorectal cancer patient-derived xenograft CLR1-1 contains radiosensitive microvasculature and stem cells. Pharmacologic or gene therapy enhancement of single dose radiotherapy-induced acid sphingomyelinase/ceramide-mediated microvascular dysfunction dramatically sensitizes CLR27-2 homologous recombination repair inactivation, converting Lgr5+ cells from the most resistant to most sensitive patient-derived xenograft population, yielding tumor cure.

conclusionWe posit homologous recombination repair represents a vulnerability determining colorectal cancer stem cell fate, approachable therapeutically using single dose radiotherapy.

Indexed as

Colorectal NeoplasmsVascular System InjuriesAnimalsCeramidesDisease Models, AnimalHumansNeoplastic Stem CellsSphingomyelin PhosphodiesteraseCeramidesSphingomyelin PhosphodiesteraseColorectal Cancer; Acid Sphingomyelinase; Ceramide; Stem Cell Fate

Identifiers

PMID36037065
PMCPMC11141240
OpenAlexW4293701637

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.